Previous studies have employed delivery of BDNF through AAV in animal models as a potential treatment for various brain pathologies, such as depression (89), stroke (43, 90), Alzheimer's disease (91), and spinal cord injury (92, 93). Here, BDNF is linked to early-onset autosomal dominant Alzheimer disease.